[Reporter's View] CSO Association set to receive official legal status

Restructuring via self-regulation

Amid President Lee Jae Myung's administration designating illicit rebate eradication as a governmental 'national normalization project' and warning of rigorous enforcement, the Ministry of Health and Welfare (MOHW) has confirmed that it is reviewing the authorization for the incorporation of the Contract Sales Organization (CSO) Association. This indicates that the MOHW has shifted to a proactive stance in reviewing the application, which had been rejected twice previously.  

The MOHW's shift in stance signifies more than merely granting official recognition to an organization. It serves as a signal for shifting CSO from being long viewed in the shadows as conduits for bypassing anti-rebate regulations to the mainstream, and for recognizing them as official dialogue partners within the regulatory framework. For the CSO Association, which has remained a temporary organization for 4 years, and forCSO  companies envisioning a clean sales ecosystem, this presents a critical window to enter the formal regulatory framework.  

While the government has laid down a path toward normalization, a fierce 'commission rate war' continues on the front lines of sales operations. Even as the government launches comprehensive status surveys on CSOs and weighs measures such as a "statutory commission rate cap", the competition over commission fees is intensifying.  

Recently, six to seven mid-tier and small-scale pharmaceutical companies implemented a wave of hikes for specific products, raising CSO commission rates by 5 to 20 percentage points. For certain hypertension combination therapies, commission rates for new prescriptions have skyrocketed to an astronomical 75%. It is a highly distorted structure where generating KRW 100 million in prescription sales results in paying out KRW 75 million to the sales agency. ​So-called "100:100 promotions," which pay out the full prescription value as a commission, also remain active. This is the outcome of an alignment of interests. Pharmaceutical manufacturers are desperate to finalize prescription accounts before the implementation of generic drug price reductions scheduled for the second half of the year. At the same time, CSOs seek to offset their mounting regulatory compliance costs.  

The industry’s duplicity, demanding integration into the formal regulatory framework while simultaneously engaging in distorted commission betting that reaches 75% to 100%, lacks credibility. ​It is difficult to accept the industry's assertion that it is "specialized sales organizations independent of illicit rebates," while leaving unaddressed a structural dynamic in which most revenue flows through agency fees. If this overactivation on the ground persists and fails to pass the MOHW's Non-Profit Corporation Review Committee, it will only lend further justification to mandatory interventions currently under executive review, such as the statutory commission rate cap system.  

Regulatory intervention is inevitably required when a market loses its capacity for self-regulation. Now that the government has opened the door to legalization and extended an entry path via the 'review of incorporation approval,' it is the absolute golden hour for the CSO industry to demonstrate its internal control and baseline corporate value.  

Ahead of electing its new chairman this summer, what the CSO Association must prepare is more than supplementing administrative paperwork. It must monitor its member firms to halt the mutually destructive race toward hyper-elevated commission rates and demonstrate tangible self-policing capabilities by expelling rogue, fragmented sub-agents that distort the market. 

Will CSOs successfully transition into the mainstream regulatory framework and emerge as legitimate partners in the pharmaceutical industry? Or will they remain blinded by short-term profits, trapped as an underground channel for illicit rebates? The government has unlocked the door. Proving that they are worthy of accepting it now depends entirely on the CSO industry.